No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis

Whether tenofovir disoproxil fumarate (TDF) is superior to entecavir in reducing hepatocellular carcinoma (HCC) risk among treatment-naïve chronic hepatitis B (CHB) patients remains controversial. We aimed to clarify this controversy. Several databases, including PubMed and Embase, were retrieved th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Jie, Peng, Yang, Hao, Fa-Bao, Wang, Ya-Qin, Wang, Chun-Rui, Zhong, Guo-Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993671/
https://www.ncbi.nlm.nih.gov/pubmed/33658397
http://dx.doi.org/10.18632/aging.202573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993671/
https://www.ncbi.nlm.nih.gov/pubmed/33658397
http://dx.doi.org/10.18632/aging.202573

Ejemplares similares